<DOC>
	<DOCNO>NCT01688713</DOCNO>
	<brief_summary>Brain metastasis , common complication , occur 25-40 % patient non-small cell lung cancer ( NSCLC ) . Whole-brain radiation therapy ( WBRT ) Stereotactic Radiosurgery ( SRS ) important approach treatment brain metastasis NSCLC . Known u , epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR-TKIs ) pas blood-brain barrier show promising antitumor activity brain metastasis NSCLC , especially EGFR mutation patient . However , due low concentration tyrosine kinase inhibitor ( TKIs ) cerebrospinal fluid inevitable emergence drug resistance , brain metastasis refractory resistant standard-dose EGFR inhibitor . Icotinib one agent EGFR-TKIs . The previous study show Icotinib conventional dose ( 125mg , TID ) far reach maximum tolerable dose . It challenge whether dose escalation Icotinib enhance concentration cerebrospinal fluid thereby improve therapeutic effect . Here investigator examine therapeutic effect side-effect double dose Icitinib treating patient brain metastasis NSCLC suffer failure conventional dose treatment .</brief_summary>
	<brief_title>Phase II Trial Double Dose Icotinib Treating Brain Metastases From Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Histological cytologic diagnosis NSCLC Patients disease progression local treatment ( WBRT and/or SRS ) combine Icotinib treatment . Patients EGFR mutation lesion remain stable 3 month local treatment ( WBRT and/or SRS ) combine Icotinib treatment . ECOG performance status 02 Doctors consider patient benefit local treatment ( WBRT and/or SRS ) Expected survival great 3 month Age : 1875 year The patient key organ maintenance basic function : Hemoglobin ≥ 9g/dL , White Blood Cell ≥ 3×109/L , Neutrophil count ≥ 1.5×109/L , platelet ≥ 80×109/L , total bilirubin &lt; 1.5 time upper normal value , Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; 2.5 upper normal value , serum creatinine &lt; 1.5 time upper normal value Signed informed consent document file . Brain metastasis without local treatment Patients without treatment Icotinib therapeutic time le 3 month More 3 extracranial organ metastatic lesion The patient type malignant tumor The patient fertility capacity , without contraceptive application</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>